Core Insights - Palisade Bio, Inc. has appointed Dr. Bram Verstockt to its Clinical Advisory Board to enhance its Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease [1][2] - The company plans to submit an Investigational New Drug (IND) application for PALI-2108 in ulcerative colitis in the first half of 2026 [1][8] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing next-generation oral PDE4 inhibitor prodrugs aimed at chronic inflammatory and fibrotic diseases [11] - The lead program, PALI-2108, is designed for targeted delivery to the terminal ileum and colon, utilizing local bacterial bioactivation to convert the prodrug into an active PDE4 inhibitor [9][10] Clinical Development - PALI-2108 has shown a 100% clinical response in a Phase 1b trial for ulcerative colitis, with no serious adverse events reported [12] - The upcoming Phase 2 study will evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, with an extension phase for maintenance of remission [13] Expert Contribution - Dr. Verstockt's expertise in inflammatory bowel disease and precision medicine will be crucial for optimizing patient selection, endpoint strategy, and disease monitoring in the Phase 2 studies [3][8] - His background in advanced imaging, biomarker integration, and multi-omics research will support the design of studies aimed at demonstrating durable efficacy and disease modification [3][6]